A study of T Cell-Antigen Coupler (TAC-T cells) for the treatment relapsing/refractory diffuse large B-cell lymphoma (DLBCL).

Trial Profile

A study of T Cell-Antigen Coupler (TAC-T cells) for the treatment relapsing/refractory diffuse large B-cell lymphoma (DLBCL).

Planning
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Cell therapies (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Mar 2018 New trial record
    • 22 Mar 2018 According to Triumvira media release,study is expecting to initiate in Q1 2019 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top